Tagged with

UK The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as its third largest export destination. However, with the Japanese government having previously expressed concern about uncertainties arising from the Brexit…

Canada As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for a number of years now, with fierce advocates on both sides of the debate.   Canada [has] some of the…

Switzerland Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to face significant delays and roadblocks in their introduction to the domestic Swiss market. Key stakeholders from pharma industry associations Interpharma and scienceindustries and local affiliate heads for multinationals Bayer…

USA In the aftermath of the fiery first presidential debate between incumbent Donald Trump and Democratic Party rival Joe Biden, we round up the latest on how the latest developments in US politics stand to affect pharma and healthcare. Featured are the two candidates’ proposals for drug pricing reform and Trump’s…

Norway Karita Bekkemellem of Norwegian pharma association LMI highlights her work building up the profile of the industry in Norway, the market access and pricing challenges facing her member companies, and the country’s enduring potential as a leading clinical trial destination.   Through diligent and long-term thinking, and building bridges and…

Norway Jan Børge Jakobsen, managing director of Bayer Norway, shares how he came to lead Bayer’s Norwegian affiliate after 30 years within the Norwegian pharma industry; Norway’s innovation capabilities in radiopharmaceuticals; and his excitement surrounding Bayer’s portfolio and upcoming product launches in Norway.   Through the acquisition and integration of Algeta,…

Switzerland scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how the country’s evolving relationship with the EU stands to impact the industry, and Switzerland’s progress on the road to full digitalisation and Pharma 2.0   What our members want is a good and stable…

Norway Philipp Maerz, the recently appointed head of Merck’s Nordic and Baltic operations and GM for Norway, outlines the challenges of taking on a new management role in the midst of a global pandemic, the innovation-friendliness of the markets under his remit, and his strategy for the cluster.   Culture eats…

Switzerland Axel Steiger, CEO and CFO for Bayer Switzerland, outlines the importance of the Swiss operations as one of the key global hubs for Bayer, his leadership and talent management philosophy, the investment and commitment Bayer is making towards becoming a global oncology player, as well as his perspectives on digital…

USA Dr Peter Marks MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), highlights the Center’s contributions related to the regulatory science behind vaccine development, including vaccines to prevent COVID-19; the Center’s efforts to facilitate the advancement of the field…

Switzerland Interpharma CEO Dr René P Buholzer outlines the holistic strategy that needs to be put in place to maintain Switzerland’s leading position in innovation, market access and reimbursement challenges for new medicines, and why an open, globalised Europe is key for security of supply.   The challenge for the future…

Roundup The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and AstraZeneca’s joint move to strengthen their manufacturing collaborations, and whether President Duterte’s vaccine diplomacy can kickstart the domestic Filipino pharma industry.   Alvotech and DKSH have expanded their partnership to commercialize six new biosimilar…